North America Thalassemia Market Size & Outlook, 2023-2030
North America thalassemia market highlights
- An overview of the North America thalassemia market trends heading towards 2030. The North America market generated a revenue of USD 363.4 million in 2023.
- The overall growth of the North America market from 2023 to 2030. The market is expected to grow at a CAGR of 7.3% from 2024 to 2030.
- A look at the North America market revenues per segment in 2023. In terms of segment, iron chelating drugs was the largest revenue generating treatment in 2023.
- The segment witnessing the fastest revenue growth within the market. Iron Chelating Drugs is the most lucrative treatment segment registering the fastest growth during the forecast period.
North America data book summary
| Market revenue in 2023 | USD 363.4 million |
| Market revenue in 2030 | USD 596.4 million |
| Growth rate | 7.3% (CAGR from 2023 to 2030) |
| Largest segment | Iron chelating drugs |
| Fastest growing segment | Iron Chelating Drugs |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Iron Chelating Drugs |
Other key industry trends
- In terms of revenue, North America region accounted for 42.8% of the global thalassemia market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 326.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Thalassemia Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Chiesi Farmaceutici | View profile | 5001-10000 | Parma, Emilia-Romagna, Italy, Europe | https://www.chiesi.com/en/ |
| Vertex Pharmaceuticals Incorporated | View profile | - | - | - |
| Sun Pharmaceutical Industries Ltd. | View profile | - | - | - |
| Fresenius Kabi AG | View profile | 10001+ | Bad Homburg, Hessen, Germany, Europe | https://www.fresenius-kabi.com |
| Apotex Inc. | View profile | 10001+ | Toronto, Ontario, Canada, North America | http://www.apotex.com |
| Bluebird bio Inc | View profile | 323 | 455 Grand Union Boulevard, Somerville, MA, United States, 02145 | https://www.bluebirdbio.com |
| Cipla Ltd DR | View profile | 38955 | Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, India, 400 013 | https://www.cipla.com |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
North America thalassemia market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to thalassemia market will help companies and investors design strategic landscapes.
Iron chelating drugs was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the North America thalassemia market based on iron chelating drugs covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to North America thalassemia market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America thalassemia market databook
-
Our clientele includes a mix of thalassemia market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America thalassemia market , including forecasts for subscribers. This continent databook contains high-level insights into North America thalassemia market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
